- HK$36.60bn
- HK$21.56bn
- CNY17.70bn
Brief: 3SBio Says All Arrangements For Bydureon License Products Terminated
Brief: 3SBio Expecs A Notable Reduction Of Financial Contribution By Sunshine Guojian To Group For FY2020
Brief: 3Sbio Inc Says Cipterbin Accepted For Listing On 2020 National Reimbursement Drug List
Brief: 3Sbio Says China's NMPA Accepted Its Ind Application For Bevacizumab Biosimilar In Mainland China
Brief: 3Sbio Gets Acceptance Of Marketing Authorization Application For Ampholipad In Mainland China
Brief: 3Sbio Obtained Approval From NMPA To Launch Nadroparin Calcium Injection
Brief: 3Sbio Inc Posts HY Net Profit Attributable Rmb702.5 Million, Up 118.6%
HK-listed 3SBio hits 8-month high on unit's Shanghai IPO progress
Brief: 3Sbio Inc Says Sunshine Guojian Will Launch Proposed IPO On 13 July
Brief: 3SBio Inc Updates On Proposed Spin-Off Of Sunshine Guojian Pharmaceutical (Shanghai)
Brief: 3Sbio Inc Says Approval Obtained For Inetetamab, First Innovative Anti-Her2 Monoclonal Antibody
Brief: 3Sbio Inc Announces Issue Of Eur 320 Mln Zero Coupon Convertible Bonds Due 2025
Brief: 3SBio Says Writ Of Summons Issued By Individual Against Co
Brief: 3SBio Inc Appoints Wang Fei Been As CFO
Brief: 3Sbio Repurchased Aggregate Principal Amount Of Eur5 Million In Face Value Of Bonds Through Over--Counter Market
Brief: 3Sbio Inc Says NMPA Approved Clinical Trial Application For Anti-Il-5 Humanized Monoclonal Antibody Injection
Brief: 3Sbio Says Unit And Numab Collaborate To Develop Portfolio Of Novel Multi-Specific Antibodies
Brief: 3Sbio Inc Says Tan Bo Has Resigned As An Executive Director
Brief: 3SBio Inc Says Clinical Trial Application Of Group's Hif-117 Capsule Approved By NMPA